Professor Stephen Gough, a renowned clinical and research specialist in diabetes, is senior principal clinical scientist and Vice-President at Novo Nordisk.
Professor Gough is responsible for providing clinical guidance on the development of new molecules and drugs from early stage through to Phase III and beyond for the treatment of diabetes and obesity at Novo Nordisk within the Global Chief Medical Office. Professor Gough joined Novo Nordisk from the Oxford Centre for Diabetes Endocrinology and Metabolism (OCDEM), where he helped develop translational research focusing on novel agents for type 1 and type 2 diabetes and beta cell replacement therapy. At Oxford, he led active diabetes research groups with a focus on pancreas and islet cell transplantation and the genetic basis to autoimmunity. He was a founder member of the UK National Welcome Trust Case Control Consortium for genetic studies in common diseases. As a practicing clinician Professor Gough also provided diabetes in-patient and out-patient care at the Oxford University Hospitals NHS Trust.
Previously he was Professor of Medicine at the University of Birmingham and consultant physician with a special interest in diabetes at the University Hospitals and Birmingham National Health Service Foundation Trust.
Cooper JD, Simmonds MJ, Walker NM, Burren O, Brand OJ, Guo H, Wallace C, Stevens H, Coleman G; Wellcome Trust Case Control Consortium, Franklyn JA, Todd JA, Gough SC. Seven newly identified loci for autoimmune thyroid disease. Hum Mol Genet. 2012 21(23):5202-8
Gough SC, Bhargava A, Jain R, Mersebach H, Rasmussen S, Bergenstal RM. Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial. Diabetes Care. 2013; 36(9): 2536-42
Mittal S, Nagendran M, Franklin RH, Sharples EJ, Friend PJ, Gough SC. Postoperative impaired glucose tolerance is an early predictor of pancreas graft failure. Diabetologia 2014; 57(10): 2076-80
Gough SC, Bode B, Woo V, Rodbard HW, Linjawi S, Poulsen P, Damgaard LH, Buse JB. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naïve patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2014; 2(11): 885-93
Hamilton A, Mittal S, Barnardo MC, Fuggle SV, Friend P, Gough SC, Simmonds MJ. Genetic variation in caveolin-1 correlates with long-term pancreas transplant function. Am J Transplant. 2015; 15 (5):1392-9
Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, Hazlehurst JM, Guo K; LEAN trial team, Abouda G, Aldersley MA, Stocken D, Gough SC, Tomlinson JW, Brown RM, Hübscher SG, Newsome PN. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016; 387 (10019): 679-90